Walvax Biotechnology Co., Ltd.

Walvax Biotechnology Co., Ltd. is a prominent Chinese biopharmaceutical company established in 2001 and listed on the Shenzhen Stock Exchange in 2010. The company specializes in the research, development, manufacturing, and distribution of innovative human vaccines, positioning itself as a leader in the Chinese pharmaceutical manufacturing industry. Walvax is recognized for its extensive product pipeline, which includes vaccines for various infectious diseases, and has built a strong reputation through collaborations with international organizations such as WHO, UNICEF, and GAVI. The company's primary business lines focus on the production of vaccines aimed at preventing severe infectious diseases. Key products include the 13-valent Pneumococcal Conjugate Vaccine and the Human Papillomavirus Vaccine, along with other vaccines for Haemophilus influenzae type b, meningococcal diseases, and DTaP. Walvax operates a state-of-the-art manufacturing facility in Yuxi, Yunnan, with a significant production capacity. The company boasts advanced research and development technology platforms, holds numerous patents, and employs a highly qualified team, enhancing its capabilities in both manufacturing and commercialization.

1. Two Global blockbuster products Walvax owns the products for 13-valent Pneumococcal Conjugate Vaccine and Human Papillomavirus Vaccine. In addition, Walvax has quadrivalent Meningococcal Conjugate Vaccine in the R&D pipeline. 2. Industry-leading R&D platform and capacity Walvax has established advanced research and development technology platforms for human vaccines and owns plenty of state-level qualifications, such as National High-tech Enterprise, National Certified Enterprise Technology Center, etc. Additionally, Walvax has over 71 patents that have been granted in China and foreign countries. 3. High standard and stringent manufacturing and quality management system as well as globally advanced commercialization capability Walvax has established a manufacturing site with annual production capacity of 170 million doses at full load for vaccines including Haemophilus influenzae type b conjugate vaccine in vial and prefilled presentation, 13-valent Pneumococcal Conjugate Vaccine in vial and prefilled presentation, Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine in vial and prefilled presentation, 23-valent Pneumococcal polysaccharide vaccine in vial and prefilled presentation, lyophilized Group A and C meningococcal polysaccharide conjugate vaccine in vial and prefilled presentation, Group ACYW135 meningococcal polysaccharide vaccine in vial and prefilled presentation, lyophilized Group A and C meningococcal polysaccharide vaccine and adsorbed DTaP vaccine. 4. Top-notch core team and professional training mechanism Walvax has over 200 employees with Master's or PhD degrees.